Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Institut de Recherches Internationales Servier
With
ADIR, a Servier Group company
Age
19–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients who are prescribed ONIVYDE per investigator's judgment shall be included if:
Patient / legally authorized representative/ family member gave written informed consent
Patient is indicated for treatment according to ONIVYDE South Korea prescribing information
Histologically or cytologically confirmed adenocarcinoma of exocrine pancreas
Documented metastatic disease
You may not be if
Adequate hepatic, renal and hematological function
Patients enrolled in Servier sponsored ONIVYDE Registry or any other Servier sponsored ONIVYDE study
Patients who have experienced severe hypersensitivity reaction to ONIVYDE or Irinotecan HCL
Patients with new or progressive dyspnea, cough, and fever, pending diagnostic evaluation of interstitial lung disease. Patients with confirmed diagnosis of interstitial lung disease
Clareo Health | Post Marketing Surveillance Study for ONIVYDE® in South Korea
